Kairos Pharma, LTD. financial data

Symbol
KAPA on NYSE
Location
Los Angeles, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 755 %
Return On Equity -79.19 %
Return On Assets -71.19 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 20,821,353 shares +62.1%
Common Stock, Shares, Outstanding 20,821,353 shares +62.1%
Common Stock, Value, Issued 21,000 USD +61.5%
Weighted Average Number of Shares Outstanding, Basic 20,206,033 shares +85.2%
Weighted Average Number of Shares Outstanding, Diluted 20,206,033 shares +85.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1,769,000 USD +42.4%
General and Administrative Expense 3,839,000 USD +1.2%
Operating Income (Loss) -5,608,000 USD -2.7%
Nonoperating Income (Expense) 546,000 USD
Net Income (Loss) Attributable to Parent -5,062,000 USD -33.5%
Earnings Per Share, Basic 0 USD/shares +30%
Earnings Per Share, Diluted 0 USD/shares +30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5,575,000 USD
Assets, Current 6,656,000 USD +40.4%
Intangible Assets, Net (Excluding Goodwill) 102,000 USD -61.1%
Assets 8,066,000 USD +61.2%
Liabilities, Current 402,000 USD -76%
Liabilities 992,000 USD -67.4%
Retained Earnings (Accumulated Deficit) -12,897,000 USD -64.6%
Stockholders' Equity Attributable to Parent 7,664,000 USD +1.3%
Liabilities and Equity 8,066,000 USD +61.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -714,000 USD -20.8%
Net Cash Provided by (Used in) Financing Activities 3,058,000 USD
Common Stock, Shares Authorized 100,000,000 shares 0%
Common Stock, Shares, Issued 20,821,353 shares +62.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2,344,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5,575,000 USD +73.3%
Deferred Tax Assets, Valuation Allowance 841,000 USD -46.8%
Deferred Tax Assets, Gross 448,000 USD
Deferred Tax Assets, Operating Loss Carryforwards 1,199,000 USD +39.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20,000,000 shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 20,540,000 USD +84.1%
Preferred Stock, Shares Outstanding 0 shares
Amortization of Intangible Assets 40,000 USD 0%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%